Caisson Establishes Partnership with CordenPharma
News Apr 21, 2016
Caisson Biotech, LLC (Caisson) has announced it has established a global manufacturing partnership with CordenPharma International (CordenPharma). Caisson has demonstrated successful technology transfer and cGMP scale-up with its corporate pharmaceutical partners utilizing its patented heparosan-based half-life extension and drug delivery platform, HEPtune®, and will establish similar capabilities with CordenPharma in order to supply licensing partners with HEPtune drug conjugate material.
As a manufacturer of the HEPtune® technology, CordenPharma will bring experience and expertise in process development and manufacture of complex carbohydrates, including carbohydrate-based polymers and glycoconjugates, which are an integral component of its Peptides, Lipids & Carbohydrates technology platform offering.
“We are excited to announce a manufacturing relationship with CordenPharma,” said Breca Tracy, PhD, Vice President and Managing Director of Caisson. “CordenPharma’s experience manufacturing carbohydrates and polyethylene glycol drug conjugates makes CordenPharma an ideal scale-up manufacturing partner and will accelerate Caisson’s capabilities to fulfill requests for larger quantities of quality material for pre-clinical and clinical studies.”
Mimoun Ayoub, PhD, Director, Global Peptides, Lipids, Carbohydrates & Injectables Platforms, CordenPharma International said, “We are delighted that Caisson Biotech has selected CordenPharma to serve as a manufacturer and supplier of HEPtune-related materials. This potentially disruptive technology is a natural fit for CordenPharma’s Peptides, Lipids & Carbohydrates platform, and we look forward to supporting Caisson Biotech’s partners as they develop and commercialize novel, life-saving therapeutics.”
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Anti-Malaria Drugs Delivered With CaffeineNews
Many drug delivery systems, such as capsules and tablets, can be difficult to swallow, especially for children. Making delivery systems out of polymer gels is an attractive option, but usually requires hazardous levels of heavy metals to be used. Now, scientists have found a way to build these gels from caffeine molecules.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018